The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 2 | -100.0% | 5.6% | Below average | |
Quality | 14 | -78.9% | 7.6% | Below average | |
Safety | 24 | 1.9x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
ImageneBio Inc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy ImageneBio Inc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ImageneBio stock shows a state of total stagnation in analyst estimates, with only one analyst covering the stock with a target price of 1.33 dollars, which is 76% lower than the current market price (5.56 dollars). Target prices have seen no change over the past 7 and 30-day periods, indicating an absence of any new catalysts or recent revisions by financial institutions.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.